Literature DB >> 22445464

Apelin, a promising target for type 2 diabetes treatment?

Isabelle Castan-Laurell1, Cédric Dray, Claude Knauf, Oxana Kunduzova, Philippe Valet.   

Abstract

Insulin resistance is a main feature of obesity and type 2 diabetes mellitus (T2DM). Several mechanisms linking obesity to insulin resistance have been proposed. Adipose tissue modulates metabolism by secreting a variety of factors, which exhibit altered production during obesity. Apelin, a small peptide present in a number of tissues and also produced and secreted by adipocytes, has emerged as a new player with potent functions in energy metabolism, and in insulin sensitivity improvement. In this review, we describe the various metabolic functions that are affected by apelin and we present an integrated overview of recent findings that collectively propose apelin as a promising target for the treatment of T2DM.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445464     DOI: 10.1016/j.tem.2012.02.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  48 in total

Review 1.  Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity.

Authors:  Chandra Kanti Chakraborti
Journal:  World J Diabetes       Date:  2015-11-10

2.  Plasma Apelin Unchanged With Acute Exercise Insulin Sensitization.

Authors:  Justin D Waller; Emily H McNeill; Frank Zhong; Lauren S Vervaecke; Allan H Goldfarb
Journal:  J Sports Sci Med       Date:  2019-08-01       Impact factor: 2.988

Review 3.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

4.  Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.

Authors:  Sophie Le Gonidec; Carline Chaves-Almagro; Yushi Bai; Hye Jin Kang; Allyson Smith; Estelle Wanecq; Xi-Ping Huang; Hervé Prats; Bernard Knibiehler; Bryan L Roth; Larry S Barak; Marc G Caron; Philippe Valet; Yves Audigier; Bernard Masri
Journal:  FASEB J       Date:  2017-02-27       Impact factor: 5.191

Review 5.  Adipose tissue, hormones, and treatment of type 1 diabetes.

Authors:  Subhadra C Gunawardana
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

6.  Genetic differences and aberrant methylation in the apelin system predict the risk of high-altitude pulmonary edema.

Authors:  Aastha Mishra; Samantha Kohli; Sanchi Dua; Tashi Thinlas; Ghulam Mohammad; M A Qadar Pasha
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

7.  Increased bone mass in mice lacking the adipokine apelin.

Authors:  Lalita Wattanachanya; Wei-Dar Lu; Ramendra K Kundu; Liping Wang; Marcia J Abbott; Dylan O'Carroll; Thomas Quertermous; Robert A Nissenson
Journal:  Endocrinology       Date:  2013-04-12       Impact factor: 4.736

Review 8.  The role of the unfolded protein response in diabetes mellitus.

Authors:  Takao Iwawaki; Daisuke Oikawa
Journal:  Semin Immunopathol       Date:  2013-03-26       Impact factor: 9.623

9.  Downregulation of the Apelinergic Axis Accelerates Aging, whereas Its Systemic Restoration Improves the Mammalian Healthspan.

Authors:  Rahul Rai; Asish K Ghosh; Mesut Eren; Alexander R Mackie; Daniel C Levine; So-Youn Kim; Jonathan Cedernaes; Veronica Ramirez; Daniele Procissi; Layton H Smith; Teresa K Woodruff; Joseph Bass; Douglas E Vaughan
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

10.  Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.

Authors:  Anne Drougard; Thibaut Duparc; Xavier Brenachot; Lionel Carneiro; Alexandra Gouazé; Audren Fournel; Lucie Geurts; Thomas Cadoudal; Anne-Catherine Prats; Luc Pénicaud; Didier Vieau; Jean Lesage; Corinne Leloup; Alexandre Benani; Patrice D Cani; Philippe Valet; Claude Knauf
Journal:  Antioxid Redox Signal       Date:  2013-09-18       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.